Early-stage cancer drug company to cut 70% of workforce, halt programs

The company, whose stock neared $49 within days of its December 2020 IPO, closed Monday at $1.70 per share.

Previous Tech firm Latch Inc., led by former Ring CEO, selects headquarters site in St. Louis
Next Thousands of Kaiser Permanente workers in Greater Washington vote to authorize strike